Impedimed Ltd has released a press release.
PREVENT Trial Successful, Statistically Significant Results
Filed with ASX ·
Watch Impedimed's latest callImpedimed (ASX:IPD) Q1 2027 Earnings Call · Replay · Oct 29Read the transcript of Impedimed (ASX:IPD) Q1 2027 Earnings Call6ix hasn’t read this filing yet.
In the deck
Earlier from Impedimed
- New Corporate Oncology Account with Icon Group
- SOZO Heart Failure Program Initiated at AdvocateAuroraHealth
- HFSA Abstracts Demonstrate Utility of SOZO for HF Patients
- Receipt of $1.8 Million R&D Tax Incentive Refund
- FDA Grants Breakthrough Device Designation for Renal Failure
Later from Impedimed
- ImpediMed Completes A$35 Million Institutional Placement
- Capital Raising Presentation
- ImpediMeds Share Purchase Plan Opens
- Share Purchase Plan Offer Booklet
- AstraZeneca extends and increases HF & Renal Contract
Follow Impedimed into a list and get an email when it puts out news.
Follow Impedimed